GRI | tickerfilter.com

Fundamental analysis

42%

Profitability 35%

Dept financing 30%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.51%

1 Month

9.59%

3 Months

16.50%

6 Months

44.58%

1 Year

-65.37%

2 Year

-70.73%

Key data

Stock price

$2.40

P/E Ratio

0.00

DAY RANGE

$2.27 - $2.41

EPS

-$55.22

52 WEEK RANGE

$0.18 - $11.12

52 WEEK CHANGE

-$64.60

MARKET CAP

806.722 K

YIELD

N/A

SHARES OUTSTANDING

1.445 M

DIVIDEND

$0.00

EX-DIVIDEND DATE

02-24-2025

NEXT EARNINGS DATE

05-09-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$46,059

AVERAGE 30 VOLUME

$238,980

Company detail

CEO: W. Marc Hertz
Region: US
Website: gribio.com
Employees: 1
IPO year: 2008

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.

GRI - GRI Bio, Inc.